![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RANBP10 |
Gene summary for RANBP10 |
![]() |
Gene information | Species | Human | Gene symbol | RANBP10 | Gene ID | 57610 |
Gene name | RAN binding protein 10 | |
Gene Alias | RANBP10 | |
Cytomap | 16q22.1 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q6VN20 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57610 | RANBP10 | AEH-subject5 | Human | Endometrium | AEH | 4.27e-02 | 1.82e-01 | -0.2953 |
57610 | RANBP10 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.84e-03 | 5.16e-02 | -0.1875 |
57610 | RANBP10 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.02e-02 | 6.09e-02 | -0.1883 |
57610 | RANBP10 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.19e-03 | 1.12e-02 | -0.1917 |
57610 | RANBP10 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.97e-04 | 2.35e-01 | -0.1269 |
57610 | RANBP10 | NAFLD1 | Human | Liver | NAFLD | 2.64e-07 | 6.54e-01 | -0.04 |
57610 | RANBP10 | HCC1_Meng | Human | Liver | HCC | 2.06e-05 | -1.38e-01 | 0.0246 |
57610 | RANBP10 | HCC2 | Human | Liver | HCC | 2.47e-04 | 2.26e+00 | 0.5341 |
57610 | RANBP10 | S028 | Human | Liver | HCC | 2.05e-04 | 3.75e-01 | 0.2503 |
57610 | RANBP10 | S029 | Human | Liver | HCC | 2.25e-02 | 2.96e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![]() | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer | ||
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RANBP10 | SNV | Missense_Mutation | c.1108N>G | p.Pro370Ala | p.P370A | Q6VN20 | protein_coding | deleterious(0.03) | benign(0.381) | TCGA-BR-8295-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
RANBP10 | SNV | Missense_Mutation | novel | c.1181C>T | p.Ala394Val | p.A394V | Q6VN20 | protein_coding | tolerated(0.3) | benign(0.009) | TCGA-VQ-A8DT-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD |
RANBP10 | SNV | Missense_Mutation | novel | c.1383N>A | p.His461Gln | p.H461Q | Q6VN20 | protein_coding | tolerated(0.07) | benign(0.3) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
RANBP10 | SNV | Missense_Mutation | c.1408N>T | p.Met470Leu | p.M470L | Q6VN20 | protein_coding | tolerated(0.71) | benign(0.001) | TCGA-FY-A3NP-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RANBP10 | insertion | In_Frame_Ins | novel | c.1156_1157insATG | p.Ser386delinsAsnGly | p.S386delinsNG | Q6VN20 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |